Product identification
Medicine name:
Suvaxyn PRRS MLV (--) - Lyophilisate and solvent for suspension for injection
Active substance:
- Porcine reproductive and respiratory syndrome virus, type 1, strain 96V198, Live
Target species:
-
Pig
Route of administration:
-
Intramuscular use
Product details
Active substance and strength:
-
Porcine reproductive and respiratory syndrome virus, type 1, strain 96V198, LivePresentation_strength:10²·² – 10⁵·² CCID₅₀ Reference:Hse Index:0
Pharmaceutical form:
-
Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
-
Intramuscular use
-
Pig
-
Not applicable0dayZero days
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI09AD03
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Available in:
-
Austria
-
Belgium
-
Denmark
-
Greece
-
Luxembourg
-
Netherlands
-
Spain
Package description:
- Packaging:Lyophilisate: vial (glass), solvent: vial (HDPE), Package_size:1 vial of lyophilisate, 1 vial of solvent, Content:lyophilisate: 100 doses, solvent: 50 ml
- Packaging:Lyophilisate: vial (glass), solvent: vial (HDPE), Package_size:1 vial of lyophilisate, 1 vial of solvent, Content:lyophilisate: 125 doses, solvent: 250 ml
- Packaging:Lyophilisate: vial (glass), solvent: vial (HDPE), Package_size:1 vial of lyophilisate, 1 vial of solvent, Content:lyophilisate: 50 doses, solvent: 100 ml
- Packaging:Lyophilisate: vial (glass), solvent: vial (HDPE), Package_size:1 vial of lyophilisate, 1 vial of solvent, Content:lyophilisate: 25 doses, solvent: 50 ml
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Manufacturing sites for batch release:
- Zoetis Belgium
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
Documents
Combined File of all Documents
English (PDF)
Download Published on: 1/05/2025
Danish (PDF)
Published on: 1/05/2025
Bulgarian (PDF)
Published on: 1/05/2025
German (PDF)
Published on: 1/05/2025
Czech (PDF)
Published on: 1/05/2025
Greek (PDF)
Published on: 1/05/2025
Spanish (PDF)
Published on: 1/05/2025
Swedish (PDF)
Published on: 1/05/2025
Estonian (PDF)
Published on: 1/05/2025
Finnish (PDF)
Published on: 1/05/2025
French (PDF)
Published on: 1/05/2025
Croatian (PDF)
Published on: 1/05/2025
Hungarian (PDF)
Published on: 1/05/2025
Icelandic (PDF)
Published on: 1/05/2025
Latvian (PDF)
Published on: 1/05/2025
Dutch (PDF)
Published on: 1/05/2025
Italian (PDF)
Published on: 1/05/2025
Lithuanian (PDF)
Published on: 1/05/2025
Maltese (PDF)
Published on: 1/05/2025
Slovak (PDF)
Published on: 1/05/2025
Polish (PDF)
Published on: 1/05/2025
Portuguese (PDF)
Published on: 1/05/2025
Slovenian (PDF)
Published on: 1/05/2025
Romanian (PDF)
Published on: 1/05/2025
Norwegian (PDF)
Published on: 1/05/2025
ema-puar-v4276-suvaxynprrsmlv-vra0011g-en.pdf
English (PDF)
Download Published on: 9/10/2024
ema-puar-v4276-suvaxyn-prrs-mlv-vra-0006-g-en.pdf
English (PDF)
Download Published on: 3/07/2023
ema-puar-suvaxyn-prrs-mlv-v-4276-par-en.pdf
English (PDF)
Download Published on: 16/03/2023
ema-puar-suvaxyn-prrs-mlv-v-4276-var-ii-0004-g-en.pdf
English (PDF)
Download Published on: 16/03/2023